PHARMACY

Greenstone intros authorized generic version of Vibramycin Hyclate

BY Ryan Chavis

PEAPACK, N.J. — Greenstone, a subsidiary of Pfizer, announced the introduction of doxycycline hyclate capsules, USP to its line of products. 
 
The drug, an authorized generic version of Vibramycin Hyclate capsules, is offered by the company in 100-mg dosage strengths in variations of 50 and 500 capsules per bottle.
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Cardinal Health: Patient-reported outcomes informs patient-centric care

BY Michael Johnsen

DUBLIN, Ohio — To improve the quality and reduce the costs of treatment provided to patients with complex diseases, a new series of studies being unveiled this week suggests clinicians should start by talking to patients themselves.
 
A series of new clinical studies published by Cardinal Health Specialty Solutions demonstrates the essential role that patient-reported outcomes research can play in advancing patient-centered care. The studies also illustrate the feasibility of leveraging user-friendly technology solutions to collect PRO data in real-time, at the point of care. The research will be featured at the International Society of Pharmacoeconomic and Outcomes Research annual meeting in Philadelphia, May 16-20, 2015.
 
“As our healthcare system moves toward a value-based care model, the role of the patient is becoming increasingly important. We need to reframe the way we think about care to include not only the cost and clinical effectiveness of the treatment, but also the burden of disease and therapy on the patient’s perceived sense of well-being,” said Bruce Feinberg, VP and chief medical officer of Cardinal Health Specialty Solutions. “Patient-reported outcomes are key to this equation, particularly for patients being treated for high-cost, complex diseases such as cancer or rheumatoid arthritis.”
 
Here’s an overview of some of the key findings of Cardinal Health Specialty Solutions research being presented at this year’s ISPOR annual meeting:
 
  • One study (abstract #56252 presented in poster session PHS87) used PRO to demonstrate that rheumatologists significantly underestimated the negative impact of RA disease burden and treatment on their patients’ sense of well-being. Understanding this disparity in perceptions can help physicians make effective treatment decisions that lessen the burden on patients, and can sometimes also reduce the costs of their care;
  • Another study (abstract #56274 presented in poster session PHS88) showed that PRO can be critical to identifying and managing medication access and adherence challenges for high-cost specialty drugs. Of a total of 239 oncology and rheumatology patients who were contacted at the time of their initial prescription to provide patient reported outcomes, 28% were identified as having problems that either restricted access or adherence to the drug. Armed with this information, interventions and support services were provided to address those challenges. With the support of these interventions, a medication possession ration exceeding 95% was achieved – enabling nearly all patients to initiate or continue treatment; and
  • A third study (abstract #56177 presented in poster session PHS88) proved the feasibility of collecting PRO at the point of care. In the clinical study involving 3,185 RA patients, PRO data was captured during 90% of physician visits through use of the PathWare decision support tool. The participating physicians were then able to utilize the data to inform real-time treatment decisions at the point of care.  
 
“This research demonstrates that technology can be leveraged to efficiently collect patient reported outcomes at the point of care and to help physicians better understand the impact treatment has on their patients,” said Feinberg. “Equally as important, this research reinforces that when we take the time to listen to the patient, we increase our chances of being able to remove the barriers that often get in the way of even the best-laid treatment plans. In doing so, we can move even closer to value-based care by improving patient outcomes and reducing unnecessary costs.”
 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

NACDS further bolsters government affairs team with new public health policy expert

BY Antoinette Alexander

ARLINGTON, Va. — The National Association of Chain Drug Stores has announced the hiring of Deepti A. Loharikar as director, federal and state public policy.  

Loharikar joined NACDS on May 11.  She will report to Kevin Nicholson, VP, public affairs and regulatory affairs.

In her role at NACDS, Loharikar will provide policy expertise on pharmacy issues at the state and federal levels. She will serve as the public policy expert on drug and patient safety, Internet pharmacies, consumer drug safety initiatives and related issues, providing policy analysis on proposed and enacted legislation and regulations. Loharikar will also prepare and deliver testimony and regulatory comments, and develop other advocacy materials in support of key issues that impact chain pharmacy.

“No stranger to the intersection of law and public health policy, Deepti brings a wealth of experience to her position at NACDS,” state NACDS president and CEO Steve Anderson.  “Deepti’s expertise in health policy, combined with her legal background, makes her an effective legislative and regulatory advocate for chain pharmacy.  We welcome her to NACDS’ already highly-talented government affairs team.”

Loharikar comes to NACDS from the Department of Health and Human Services where she oversaw the development and implementation of long-term strategies for the consumer-oriented and operated plan (CO-OP) insurance program. In addition, she previously served as a health policy analyst for the Federal Office of Rural Health Policy at HHS. Prior to her work for the federal government, Loharikar practiced law at a law firm in New Jersey and with the Department of Justice Washington, D.C.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?